Eli Lilly and Company
The main purpose of this study is to see if LY3985297, the study drug, is safe and well-tolerated when given as a single dose or as multiple doses either through an intravenous (into a vein) or a subcutaneous (under the skin) injection in healthy participants. Study will also evaluate how much of the study drug LY3985297 gets into the blood stream and how long it takes the body to remove it. The study is conducted in two parts (part A and B), each part has a separate treatment cohort. The study will last up to approximately 116 days for part A, and 145 days for part B, including the screening period.
Healthy
LY3985297
Placebo
Phase 1
Study Type : | Interventional |
Estimated Enrollment : | 153 participants |
Masking : | Double |
Primary Purpose : | Basic Science |
Official Title : | A Phase 1, Randomized, Placebo-controlled, Investigator and Participant Blinded, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3985297 in Healthy Participants |
Actual Study Start Date : | May 2024 |
Estimated Primary Completion Date : | July 2025 |
Estimated Study Completion Date : | July 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: Part A: LY3985297 (Cohorts 1-8) Single ascending dose of LY3985297 administered either intravenously (IV) or subcutaneously (SC). Cohort 5,6 and 7 is conducted in Japanese or Chinese participants. |
Drug: LY3985297 |
Experimental: Part B: LY3985297 (Cohorts 1-4) Multiple ascending dose of LY3985297 administered either IV or SC. |
Drug: LY3985297 |
Placebo Comparator: Placebo Comparator: Part A and B: Placebo Placebo administered either IV or SC. |
Drug: Placebo |
Ages Eligible for Study: | 18 Years to 64 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Accepts Healthy Volunteers |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
ICON
Salt Lake City, Utah, United States, 84124